Cardiovascular Danger in People With HIV

A team of US researchers discovered that current risk models underestimate cardiovascular events among people with HIV, particularly in women and Black men in high-income countries (1^✔ ✔Trusted Source
Performance of the Pooled Cohorts Equations and D:A:D Risk Scores among Individuals with HIV in a Global Cardiovascular Disease Prevention Trial: A Cohort Study Leveraging Data from REPRIEVE

Go to source).

Cardiovascular Risk in HIV: A Global Health Challenge

Cardiovascular disease is the leading cause of morbidity and mortality globally, posing a particularly significant threat to people with HIV (PWH), according to new study published in the journal Lancet HIV. Previous studies have called into question whether these commonly used prediction models perform well among people with HIV, and there remains a gap in understanding of what these scores mean for PWH in low- and middle-income countries (LMICs).

Researchers from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, in collaboration with an international team of investigators, conducted a study to evaluate how well existing atherosclerotic cardiovascular disease (ASCVD) risk estimates could be used to predict cardiovascular outcomes in global populations with HIV.

Their prospective cohort study used data from Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) to analyse individuals with HIV who were from low-, middle-, and high-income countries across several continents. The researchers found that for those in REPRIEVE, current risk models underestimated cardiovascular events in both women and black men in high income countries (HICs), while overestimating cardiovascular events for all PWH in LMICs.

“These findings allow researchers to fine-tune cardiovascular disease prediction models for people living with HIV,” said Patrice Desvigne-Nickens, a medical officer within the National Heart, Lung, and Blood Institute (NHLBI). “Assessing the accuracy of these predictions in subgroups of the population is possible because of carefully developed outreach and enrolling a diverse study population – representing all people at risk,” Desvigne-Nickens added.

According to Steven Grinspoon, chief of the Massachusetts General Hospital Metabolism Unit in the Endocrinology Division of the Department of Medicine, this study underscores the need for nuanced, region-specific and population-specific CVD prediction models that accurately reflect cardiovascular risk for PWH, including those living in LMICs.

Reference:

1. Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE - (https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(24)00276-5/abstract)

Source-IANS